Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07095868 · ClinicalTrials.gov registry record · Phase 1
Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors
A Phase 1 study of Selected Types of Solid Tumor, sponsored by Everest Medicines (Beijing) Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 94
- Enrollment target
- 7
- Study locations
NCT07095868 is a Phase 1 study of Selected Types of Solid Tumor that is actively recruiting participants, run by Everest Medicines (Beijing) Co.. The registered enrollment target is 94 participants. The trial reports 7 study locations across 6 states.
The verdict
NCT07095868, a Phase 1 study of Selected Types of Solid Tumor, is actively recruiting participants, sponsored by Everest Medicines (Beijing) Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 94 participants
- Enrollment target
- 7
- Study locations
Study Summary
Brief Summary: The purpose of this clinical trial is to evaluate the safety, tolerability, preliminary efficacy, and immunogenicity of EVM14 administered intramuscularly (IM) alone and in combination with pembrolizumab in patients with selected solid tumors.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Pembrolizumab
- BIOLOGICAL EVM14
Study Locations (7)
Jiangsu
- Nanjing Drum Tower Hospital - Nanjing
- The First Affiliated Hospital With Nanjing Medical University - Nanjing
New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- MD Anderson Cancer Center - Houston
Virginia
- NEXT Oncology - Fairfax
Hunan
- Hunan Cancer Hospital - Changsha
Shanghai Municipality
- Shanghai Chest Hospital - Shanghai
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2025-11-17 |
| Est. Completion | 2031-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07095868
The ClinicalTrials.gov registry entry for NCT07095868 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Everest Medicines (Beijing) Co., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Selected Types of Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT07095868 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Jiangsu, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT07095868 about?
NCT07095868 is a clinical study titled "Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors". Brief Summary: The purpose of this clinical trial is to evaluate the safety, tolerability, preliminary efficacy, and immunogenicity of EVM14 administered intramuscularly (IM) alone and in combination with pembrolizumab in patients with selected solid tumors.
What is the current status of trial NCT07095868?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 94 participants. The study started on 2025-11-17. Estimated completion is 2031-11.
What conditions does trial NCT07095868 study?
This clinical trial studies the following conditions: Selected Types of Solid Tumor.
What interventions are being tested in trial NCT07095868?
The interventions under investigation include: Pembrolizumab (COMBINATION_PRODUCT), EVM14 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07095868?
This trial is sponsored by Everest Medicines (Beijing) Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07095868 being conducted?
This trial has 7 study locations across New York, Texas, Virginia, Hunan, Jiangsu. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.